Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology, today announced ...

Gastrointestinal cancers often develop silently but knowing risk factors and warning signs can lead to earlier detection and ...

EvoLiver, a blood test that detects early-stage liver cancer with high accuracy, has gained breakthrough device designation ...

By analysing DNA from blood samples, Tvaster Genkalp is working to make cancer diagnostics more accessible, accurate, and ...

Pierre Arsène, founder and CEO of Mursla Bio, said: “This designation is a powerful validation of both our scientific vision ...

or liver biopsy. Negative results do not exclude the possibility of cancer and further follow-up is necessary. Although hepatocellular carcinoma (HCC) has always been recognized as a complication ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Helio Genomics ("Helio" or "the Company"), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today showcased results from three cancer ...

Prevalence and risk factors Hepatocellular carcinoma (HCC), the most common type of primary liver cancer ... “And when that doesn’t suffice, a biopsy will be carried out,” he explained.